Evidence map›Paper›PMID 15736910›Full record

ReviewLipids2004

n-3 fatty acids, inflammation, and immunity--relevance to postsurgical and critically ill patients.

Philip C Calder

2 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Lipids, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03792087 phase3completednot on this mapstarted 2017, after this paper: background citation

Efficacy & Safety of SmofKabiven Peripheral vs Compounded Emulsion: A Randomized, Active-Controlled, Open-Labelled, Multi-Centre Study in Adult Surgical Patients Requiring Parenteral Nutrition

TypeinterventionalSponsorFresenius KabiRan2017 to 2018Enrolled272ConditionsParenteral Feeding, SurgeryArmsSmofKabiven Peripheral, Hospital compounded emulsion
NCT03792100 phase3completednot on this mapstarted 2019, after this paper: background citation

Efficacy & Safety of SmofKabiven Emulsion for Infusion vs Hospital Compounded "All in One" for Parenteral Nutrition (PN): A Randomized, Active-Controlled, Patient-blinded, Multi-Centre Study in Adult Surgical Patients Requiring PN

TypeinterventionalSponsorFresenius KabiRan2019 to 2020Enrolled273ConditionsParenteral Nutrition, SurgeryArmsSmofKabiven emulsion for infusion, Hospital compounded "All in one" emulsion
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 158 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Fish oil after abdominal aorta aneurysm surgery.European journal of clinical nutrition · 2008
    Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Article
  15. Review
  16. Plasma metabolic profiling implicates dysregulated lipid metabolism and glycolytic shift in hyperinflammatory ARDS.American journal of physiology. Lung cellular and molecular physiology · 2023
    Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Philip C CalderInstitute of Human Nutrition, School of Medicine, University of Southampton, Bassett Crescent East, Southampton SO16 7PX, United Kingdom. pcc@soton.ac.uk
University of Southampton · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Excessive or inappropriate inflammation and immunosuppression are components of the response to surgery, trauma, injury, and infection in some individuals and these can lead, progressively, to sepsis and septic shock. The hyperinflammation is characterized by the production of inflammatory cytokines, arachidonic acid-derived eicosanoids, and other inflammatory mediators, while the immunosuppression is characterized by impairment of antigen presentation and of T helper cell type-1 responses. Long-chain n-3 FA from fish oil decrease the production of inflammatory cytokines and eicosanoids. They act both directly (by replacing arachidonic acid as an eicosanoid substrate and by inhibiting arachidonic acid metabolism) and indirectly (by altering the expression of inflammatory genes through effects on transcription factor activation). Thus, long-chain n-3 FA are potentially useful anti-inflammatory agents and may be of benefit in patients at risk of developing sepsis. As such, an emerging application of n-3 FA is in surgical or critically ill patients where they may be added to parenteral or enteral formulas. Parenteral or enteral nutrition including n-3 FA appears to preserve immune function better than standard formulas and appears to partly prevent some aspects of the inflammatory response. Studies to date are suggestive of clinical benefits from these approaches, especially in postsurgical patients.

Indexed as

Postoperative ComplicationsAnti-Inflammatory AgentsCritical IllnessFatty Acids, Omega-3Fatty Acids, Omega-6HumansInflammationAnti-Inflammatory AgentsFatty Acids, Omega-3Fatty Acids, Omega-6

Identifiers

PMID15736910
PMCPMC7101959
OpenAlexW1992111677

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.